Hence, drugs that impact Cyclin D1 expression are of great therapeutic interest.[29] Metformin has been shown in three prostate cancer cell lines to block cell cycle progression from G0/G1 to S as seen by a decrease in Cyclin D1, E2F1, and Rb phosphorylation. Here, CCND1 is linked to prostate cancer.